Selective inhibitors of monoamine oxidase type B and the "cheese effect"

International Review of Neurobiology

Volumn 100, Issue , 2011, Pages 169-190

  Finberg, John P M ^a   Gillman, Ken ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b PsychoTropical Research   (Australia)

Author keywords

Blood pressure; Clorgyline; Dopamine; Monoamine oxidase; Noradrenaline; Rasagiline; Selegiline; Sympathomimetic amine; Tyramine

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENZODIAZEPINE; BENZYLAMINE; BROFAROMINE; CLORGYLINE; DOPAMINE; ENTACAPONE; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; NORADRENALIN; NORADRENALIN TRANSPORTER; PHENELZINE; PLACEBO; RASAGILINE; SELEGILINE; SEROTONIN; TRANYLCYPROMINE; TYRAMINE; VESICULAR MONOAMINE TRANSPORTER;

ADJUVANT THERAPY; BEER; BOOK; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHEESE; CHEESE EFFECT; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; FISH SAUCE; FOOD; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; IC 50; MEAT; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; WINE;

EID: 80053465129     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386467-3.00009-1     Document Type: Chapter

References (97)

1. Al Bulushi I., Poole S., Deeth H.C., Dykes G.A. Biogenic amines in fish: roles in intoxication, spoilage, and nitrosamine formation-a review. Crit. Rev. Food Sci. Nutr. 2009, 49:369-377.
2. Amsterdam J.D. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J. Clin. Psychiatry 2003, 64:208-214.
3. Anli R.E., Vura N., Demiray S., Mert B. Biogenic amine content of beers consumed in Turkey and influence of storage conditions on biogenic amine formation. J. Inst. Brewing 2006, 112:267-274.
4. Azzaro A.J., Vandenberg C.M., Blob L.F., Kemper E.M., Sharoky M., Oren D.A., Campbell B.J. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6mg/24h in healthy subjects. J. Clin. Pharmacol. 2006, 46:933-944.
5. Berlin I., Zimmer R., Cournot A., Payan C., Pedarriosse A.M., Puech A.J. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin. Pharmacol. Ther. 1989, 46:344-351.
6. Berry M.D. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J. Neurochem. 2004, 90:257-271.
7. Bieck P.R., Antonin K.H. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J. Clin. Psychopharmacol. 1988, 8:237-245.
8. Bieck P.R., Antonin K.H. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J. Neural Transm. Suppl. 1989, 28:21-31.
9. Bieck P.B., Antonin K.-H. Tyramine potentiation during treatment with MAOIs. Clinical Advances in Monoamine Oxidase Inhibitor Therapies 1994, 83-110. American Psychiatric Press, Washington & London. S.H. Kennedy (Ed.).
10. Bieck P.R., Antonin K.H., Schulz R. Clinical pharmacology of monoamine oxidase inhibitors. Monoamine Oxidase: Basic and Clinical Aspects 1993, 177-196. VSP, Utrecht. H. Yasuhara, S.H. Parvez, K. Oguchi, M. Sandler, T. Nagatsu (Eds.).
11. Birkmayer W., Riederer P., Youdim M.B. (-)Deprenyl in the treatment of Parkinson's disease. Clin. Neuropharmacol. 1982, 5:195-230.
12. Blackwell B., Mabbitt L.A. Tyramine in cheese related to hypertensive crises after monoamine-oxidase inhibition. Lancet 1965, 1:938-940.
13. Blob L.F., Sharoky M., Campbell B.J., Kemper E.M., Gilmor M.G., VanDenberg C.M., Azzaro A.J. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6mg/24hour. CNS Spectr. 2007, 12:25-34.
14. Broadley K.J. The vascular effects of trace amines and amphetamines. Pharmacol. Ther. 2010, 125:363-375.
15. Burn J.H., Rand M.J. The action of sympathomimetic amines in animals treated with reserpine. J. Physiol. 1958, 144:314-336.
16. Calne D.B., Brennan J., Spiers A.S., Stern G.M. Hypotension caused by L-dopa. Br. Med. J. 1970, 1:474-475.
17. Cho T.Y., Han G.H., Bahn K.N., Son Y.W., Jang M.R., Lee C.H., Kim S.H., B K.D., Kim S.B. Evaluation of biogenic amines in Korean commercial fermented foods. Korean J. Food Sci. Technol. 2006, 38:730-737.
18. Churchyard A., Mathias C.J., Boonkongchuen P., Lees A.J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 63:228-234.
19. Clarke A., Johnson E.S., Mallard N., Corn T.H., Johnston A., Boyce M., Warrington S., MacMahon D.G. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J. Neural Transm. 2003, 110:1257-1271.
20. Cortacero-Rami{dotless}rez S., Arraez-Roman D., Antonio Segura-Carretero A., Fernandez-Gutierrez A. Determination of biogenic amines in beers and brewing-process samples by capillary electrophoresis coupled to laser-induced fluorescence detection. Food Chem. 2007, 100:383-389.
21. Da Prada M., Zurcher G. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology (Berlin) 1992, 106(Suppl.):S32-S34.
22. deMarcaida J.A., Schwid S.R., White W.B., Blindauer K., Fahn S., Kieburtz K., Stern M., Shoulson I. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov. Disord. 2006, 21:1716-1721.
23. Elsworth J.D., Glover V., Reynolds G.P., Sandler M., Lees A.J., Phuapradit P., Shaw K.M., Stern G.M., Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 1978, 57:33-38.
24. Finberg J.P., Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br. J. Pharmacol. 1982, 77:13-21.
25. Finberg J.P., Youdim M.B. Selective MAO A and B inhibitors: their mechanism of action and pharmacology. Neuropharmacology 1983, 22:441-446.
26. Finberg J.P., Youdim M.B. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002, 43:1110-1118.
27. Finberg J.P., Gross A., Bar-Am O., Friedman R., Loboda Y., Youdim M.B. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat. Br. J. Pharmacol. 2006, 149:647-656.
28. Fischer J.E., Horst W.D., Kopin I.J. Beta-hydroxylated sympathomimetic amines as false neurotransmitters. Br. J. Pharmacol. Chemother. 1965, 24:477-484.
29. Flanigan J.S., Vitberg D. Hypertensive emergency and severe hypertension: what to treat, who to treat, and how to treat. Med. Clin. North Am. 2006, 90:439-451.
30. Fowler J.S., Volkow N.D., Logan J., Schlyer D.J., MacGregor R.R., Wang G.J., Wolf A.P., Pappas N., Alexoff D., Shea C., et al. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology 1993, 43:1984-1992.
31. Fozard J.R., Zreika M., Robin M., Palfreyman M.G. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145. Naunyn Schmiedebergs Arch. Pharmacol. 1985, 331:186-193.
32. Frascarelli S., Ghelardoni S., Chiellini G., Vargiu R., Ronca-Testoni S., Scanlan T.S., Grandy D.K., Zucchi R. Cardiac effects of trace amines: pharmacological characterization of trace amine-associated receptors. Eur. J. Pharmacol. 2008, 587:231-236.
33. Gillman P.K. Advances pertaining to the pharmacology and interactions of irreversible non-selective monoamine oxidase inhibitors. J. Clin. Psychopharmacol. 2011, 31:66-74.
34. Gillman P.K. Monoamine oxidase inhibitors, dietary tyramine and drug interactions 2011, [accessed Dec 2010]. http://psychotropical.com/pdfs/maois_diet_full.pdf.
35. Glezer S., Finberg J.P. Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur. J. Pharmacol. 2003, 472:173-177.
36. Goren T., Adar L., Sasson N., Weiss Y.M. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. J. Clin. Pharmacol. 2010, 50:1420-1428.
37. Hare M.L. Tyramine oxidase: a new enzyme system in liver. Biochem. J. 1928, 22:968-979.
38. Hasan F., McCrodden J.M., Kennedy N.P., Tipton K.F. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J. Neural Transm. Suppl. 1988, 26:1-9.
39. Haykowsky M.J., Findlay J.M., Ignaszewski A.P. Aneurysmal subarachnoid hemorrhage associated with weight training: three case reports. Clin. J. Sport Med. 1996, 6:52-55.
40. Ibe A., Tabata S., Sadamasu Y., Yasui A., Shimoi T., Endoh M., Saito K. Production of tyramine in "moromi" mash during soy sauce fermentation. Shokuhin Eiseigaku Zasshi 2003, 44:220-226.
41. Isaacson S.H. Selective MAO-B inhibitors have low potential for the tyramine effect. Mov. Disord. 2008, 25:123-124.
42. Jacob G., Gamboa A., Diedrich A., Shibao C., Robertson D., Biaggioni I. Tyramine-induced vasodilation mediated by dopamine contamination: a paradox resolved. Hypertension 2005, 46:355-359.
43. Jarrott B., Iversen L.L. Noradrenaline metabolizing enzymes in normal and sympathetically denervated vas deferens. J. Neurochem. 1971, 18:1-6.
44. Jessen L., Kovalick L.J., Azzaro A.J. The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder. Pharmacy Ther. 2008, 33:212-246.
45. Kalac P., Glória M.B.A. Biogenic amines in cheeses, wines, beers and sauerkraut. Biological Aspects of Biogenic Amines, Polyamines and Conjugates 2009, 267-309. Transworld Research Network, Kerala, India. G. Dandrifosse (Ed.).
46. Kalac P., Krízek M. A review of biogenic amines and polyamines in beer. J. Inst. Brewing 2003, 109:123-128.
47. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 1972, 5:393-408.
48. Knoll J., Ecsery Z., Magyar K., Satory E. Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem. Pharmacol. 1978, 27:1739-1747.
49. Komprda T., Burdychova R., Dohnal V., Cwikova O., Sladkova P., Dvorackova H. Some factors influencing biogenic amines and polyamines content in Dutch-type semi-hard cheese. Eur. Food Res. Technol. 2008, 227:29-36.
50. Komprda T., Burdychova R., Dohnal V., Cwikova O., Sladkova P., Dvorackova H. Tyramine production in Dutch-type semi-hard cheese from two different producers. Food Microbiol. 2008, 25:219-227.
51. Komprda T., Dohnal V., Závodníková R. Contents of some biologically active amines in a Czech blue-vein cheese. Czech J. Food Sci. 2008, 26:428-440.
52. Krausová P., Kalač P., Křížek M., Pelikánová T. Content of biologically active polyamines in livers of cattle, pigs and chickens after animal slaughter. Meat Sci. 2006, 73:640-644.
53. Lader M.H., Sakalis G., Tansella M. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 1970, 18:118-123.
54. Laine K., Anttila M., Huupponen R., Maki-Ikola O., Heinonen E. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin. Neuropharmacol. 2000, 23:22-27.
55. Lamensdorf I., Porat S., Simantov R., Finberg J.P. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br. J. Pharmacol. 1999, 126:997-1002.
56. Lavian G., Di Bona G., Finberg J.P. Inhibition of sympathetic nerve activity by acute administration of the tricyclic antidepressant desipramine. Eur. J. Pharmacol. 1991, 194:153-159.
57. Lorenzo J.M., Martínez S., Francoa I., Carballo J. Biogenic amine content during the manufacture of dry-cured lacón, a Spanish traditional meat product: effect of some additives. Meat Sci. 2007, 77:287-293.
58. Loret S., Deloyer P., Dandrifosse G. Levels of biogenic amines as a measure of the quality of the beer fermentation process: data from Belgian samples. Food Chem. 2005, 89:519-525.
59. Mann J.J., Aarons S.F., Wilner P.J., Keilp J.G., Sweeney J.A., Pearlstein T., Frances A.J., Kocsis J.H., Brown R.P. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry 1989, 46:45-50.
60. Mawhinney M., Cole D., Azzaro A.J. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J. Pharm. Pharmacol. 2003, 55:27-34.
61. Meck J.V., Martin D.S., D'Aunno D.S., Waters W.W. Pressor response to intravenous tyramine is a marker of cardiac, but not vascular, adrenergic function. J. Cardiovasc. Pharmacol. 2003, 41:126-131.
62. Mendlewicz J., Youdim M.B. L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br. J. Psychiatry 1983, 142:508-511.
63. Murphy D.L., Karoum F., Pickar D., Cohen R.M., Lipper S., Mellow A.M., Tariot P.N., Sunderland T. Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J. Neural Transm. Suppl. 1998, 52:39-48.
64. Novella-Rodriguez S., Veciana-Nogues M.T., Izquerdo-Pulido M., Vidal-Carou M.C., Roig-Sagues A.X., Trujillo-Mesa A.J. Distribution of biogenic amines and polyamines in cheese. J. Food Sci. 2003, 68:750-755.
65. O'Carroll A.M., Fowler C.J., Phillips J.P., Tobbia I., Tipton K.F. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch. Pharmacol. 1983, 322:198-202.
66. Opatrny L., Delaney J.A., Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br. J. Clin. Pharmacol. 2008, 66:76-81.
67. Ottervanger J.P., Klaver M.M., Kolling P., Stricker B.H. Intracranial hemorrhage following use of MAO inhibitor tranylcypromine and beer. Nederlands Tijdschrift Voor Geneeskunde 1993, 137:921-922.
68. Pae C.U., Lim H.K., Han C., Neena A., Lee C., Patkar A.A. Selegiline transdermal system: current awareness and promise. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1153-1163.
69. Parkinson A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 2002, 59:1937-1943.
70. Philips S.R., Durden D.A., Boulton A.A. Identification and distribution of p-tyramine in the rat. Can. J. Biochem. 1974, 52:366-373.
71. Pintadoa A.I.E., Pinho O., Ferreira I.M.P.L.V.O., Pintadoa M.M.E., Gomesa A.M.P., Malcataa F.X. Microbiological, biochemical and biogenic amine profiles of Terrincho cheese manufactured in several dairy farms. Int. Dairy J. 2008, 18:631-640.
72. Pirri J.K., McPherson A.D., Donnelly J.L., Francis M.M., Alkema M.J. A tyramine-gated chloride channel coordinates distinct motor programs of a Caenorhabditis elegans escape response. Neuron 2009, 62:526-538.
73. Populin T., Moret S., Truant S., Lanfranco S., Conte L.S. A survey on the presence of free glutamic acid in foodstuffs, with and without added monosodium glutamate. Food Chem. 2007, 104:1712-1717.
74. PRESTO A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 2005, 62:241-248.
75. Pursiainen V., Korpelainen T.J., Haapaniemi H.T., Sotaniemi A.K., Myllyla V.V. Selegiline and blood pressure in patients with Parkinson's disease. Acta Neurol. Scand. 2007, 115:104-108.
76. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
77. Robinson D.S., Amsterdam J.D. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J. Affect. Disord. 2008, 105:15-23.
78. Ruiz-Capillas C., Jimenez-Colmenero F. Biogenic amine content in Spanish retail market meat products treated with protective atmosphere and high pressure. Eur. Food Res. Technol. 2004, 218:237-241.
79. Schmidt N., Ferger B. The biogenic trace amine tyramine induces a pronounced hydroxyl radical production via a monoamine oxidase dependent mechanism: an in vivo microdialysis study in mouse striatum. Brain Res. 2004, 1012:101-107.
80. Shalaby A.R. Significance of biogenic amines to food safety and human health. Food Res. Int. 1996, 29:675-690.
81. Stute R.K., Petridis H., Steinhart A., Biernoth G. Biogenic amines in fish and soy sauce. Eur. Food Res. Technol. 2002, 215:101-107.
82. Sunderland T., Cohen R.M., Molchan S., Lawlor B.A., Mellow A.M., Newhouse P.A., Tariot P.N., Mueller E.A., Murphy D.L. High-dose selegiline in treatment-resistant older depressive patients. Arch. Gen. Psychiatry 1994, 51:607-615.
83. Suzzi G., Gardini F. Biogenic amines in dry fermented sausages: a review. Int. J. Food Microbiol. 2003, 88:41-54.
84. Tailor S.A., Shulman K.I., Walker S.E., Moss J., Gardner D. Hypertensive episode associated with phenelzine and tap beer-a reanalysis of the role of pressor amines in beer. J. Clin. Psychopharmacol. 1994, 14:5-14.
85. Tang T., Shi T., Qian K., Li P., Li J., Cao Y. Determination of biogenic amines in beer with pre-column derivatization by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:507-512.
86. Trendelenburg U., Langeloh A., Bonisch H. Mechanism of action of indirectly acting sympathomimetic amines. Blood Vessels 1987, 24:261-270.
87. VanDenBerg C.M., Blob L.F., Kemper E.M., Azzaro A.J. Tyramine pharmacokinetics and reduced bioavailability with food. J. Clin. Pharmacol. 2003, 43:604-609.
88. Waldmeier P.C., Felner A.E., Maitre L. Long-term effects of selective MAO inhibitors on MAO activity and amine metabolism. Monoamine Oxidase Inhibitors, the State of the Art 1981, 87-102. Wiley, New York. M.B.H. Youdim, E.S. Paykel (Eds.).
89. White W.B., Salzman P., Schwid S.R. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. Hypertension 2008, 52:587-593.
90. Yongmeia L., Xiaohonga C., Meia J., Xina L., Rahmanb N., Mingshenga D., Yanc G. Biogenic amines in Chinese soy sauce. Food Control 2009, 20:593-597.
91. Youdim M.B.H., Finberg J.P.M. Monoamine oxidase inhibitor antidepressants. Psychopharmacology 1983, 38-70. Excerpta Medica, Amsterdam. D.G. Grahame-Smith, P.J. Cowen (Eds.).
92. Youdim M.B., Finberg J.P. Monoamine oxidase B inhibition and the "cheese effect" J. Neural Transm. Suppl. 1987, 25:27-33.
93. Youdim M.B.H., Finberg J.P.M., Tipton K.F. Amine oxidases. Handbook of Experimental Pharmacology 1988, 119-192. Springer Verlag, Berlin. U. Trendlenburg, N. Weiner (Eds.).
94. Youdim M.B., Gross A., Finberg J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 2001, 132:500-506.
95. Youdim M.B., Edmondson D., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7:295-309.
96. Zaman M.Z., Abdulamir A.S., Bakar F.A., Jinap Selamat J., Bakar J. A review: microbiological, physicochemical and health impact of high level of biogenic amines in fish sauce. Am. J. Appl. Sci. 2009, 6:1199-1211.
97. Zimmer R., Puech A.J., Philipp F., Korn A. Interaction between orally administered tyramine and moclobemide. Acta Psychiatr. Scand. Suppl. 1990, 360:78-80.